colorectal cancer
Conditions
Interventions
1st line chemotheraypy: SOX+Bmab Bmab: 7.5mg/kg every 3weeks L-OHP: 130mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 2nd line chemotheraypy: SIR+Bmab Bmab: 7.5mg
Sponsors
Chiba surgical oncology development association
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Confirmed adenocarcinoma 2) Unresectable colon or rectal cancer 3) 20 >=, <80 years old 4) Performance status(ECOG): 0-1 5) Evaluable lesion by CT, MRI and X-ray within 30 days 6) No previous treatment 7) No abnormally electrocardiogram 8) Oral intake is possible 9) Adequate organ fanction 10) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Serious drug hypersensitivity 2) Pregnant or nursing 3) Active infection 4) Serious coexisting illness diabetes mellitus, uncontrolled or controlled with insulin, uncontrolled hypertension, liver cirrhosis, renal disfaunction, severe pulmonary dysfunction, active infection, history of myocardial infarction 5) Gastrointestinal ulcer or bleeding 6) Sensory neuropathy 7) Hydrothorax or ascites which needs treatment 8) Brain metastasis 9) Gastrointestinal perforation within 6 months 10) Cerebral infarction, myocardial infarction, pulmonary infarction and interstitial pneumonia 11) Operation within 28 dys 12) Congenital bleeding factor 13) Anticoagulation drugs are given to 14) Active synchronous or metachronous malignancy other than carcinoma in situ 15) Past of the hemoptysis 16) Case having the primary lesion genesis with high stenosis 17) The case that peritoneum dissemination or a peritoneum nodule is confirmed with an image 18) Case taking Flucytosine or Atazanavir Sulfate 19) Diarrea 20) Choloplania 21) The continuous case that receive it systematically of the steroid 22) Atopic dermatitis 23) Not suitable for participating in the study for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival:OS | — |
Countries
Japan
Contacts
Public ContactHideaki Miyauchi
Chiba surgical oncology development association The secretariat
Outcome results
None listed